What’s New in Neurology?
In the field of neurology, there have been new prescription medications approved by the Food and Drug Administration (FDA) since the beginning of 2019. These medications have undergone the rigorous research and approval process to ensure safety and efficacy, however, the pharmaceutical companies will continue to monitor this in the post-market phase.
Mavenclad (cladribine) and Mayzent (siponimod):
These two disease modifying therapies have been approved for use in relapsing forms of multiple sclerosis. Although multiple sclerosis does not have a cure, these new medications add to the growing list of therapies that help prevent relapses and disability caused by this disease.
Midazolam has been available under different brand names previously but Nayzilam is the first nasal spray formulation of this medication for intranasal administration. This is approved for use in patients 12 years of age and older who suffer from acute repetitive seizures, or seizure clusters.
Spravato is a nasal spray indicated for treatment-resistant depression in adults. This must be used in conjunction with an oral antidepressant and offers an additional option for those who have struggled with treatment-resistant depression. This medication is not approved in children.
Sumatriptan has also been available under different brand names for acute treatment of migraines with or without aura. Tosymra is the first nasal spray formulation of sumatriptan and offers patients a different route of administration other than oral or subcutaneous (which may take longer to have an effect on symptoms).
Neurology isn’t the only area of medicine that has newly-approved medications available over the past year.
Here’s a link to find out more about other FDA-approved medications:
*As with any medication, these listed above come with important side effects and warnings that patients need to be aware of and counseled on. Check with your physician or pharmacist for further information about these products.*